Vasospastic angina is rarely observed during cancer treatment. The present report describes two males with lung cancer, aged 73 and 61, who developed vasospastic angina during combination treatment of cisplatin-containing chemotherapy and thoracic irradiation. As both patients have smokedand their ages are typical for patients with coronary artery disease, such events may be incidental. However, oncologists should be aware of the possible development of myocardial ischemia during or following administration of antineoplastic agents, especially in elderly patients with pre-existing coronary risk factors or a history of thoracic radiotherapy. (Internal Medicine 38: 436-438, 1999) 
Introduction
Cancer chemotherapy is rarely associated with coronary artery diseases (CAD) compared with the relatively high frequency of hematological and gastrointestinal toxicities, although patients with cancer are usually of similar age to those with CAD.However, few reports have described vascular toxicities including CAD,associated with the use of antineoplastic agents or radiotherapy (1, 2) . In these reports, a variety of agents, such as vinca alkaloids, 5-fluorouracil, etoposide and cisplatin, were used either singularly or in combination (3). In the present report, we describe two cases of vasospastic angina probably related to cisplatin-containing chemotherapy with thoracic irradiation for lung cancer.
Case Report Patient 1 A 73-year-old male was admitted to our hospital in July 1996, for further evaluation of an abnormal shadow detected on a routine chest radiograph. The patient, who was a smoker (20 cigarettes a day for 53 years), developed a cough with bloody sputum in May 1996. A chest radiograph showed a mass in the left upper lung field apicomedialy. The tumor was cytologically diagnosed as adenocarcinoma, and the clinical stage was evaluated as IIIA (cT3N0M0). Thoracotomy was performed onAugust 20, 1996. Thetumor, 6.5 x 5.5 x 3.0cm in size, was located in the left apicoposterior segment. The left upper lobe waspartially resected, since the tumor and the enlarged mediastinal lymph nodes were densely adherent to the mediastinum and the parietal pleura. The surgical stage was finally evaluated as IIIB (sT4N2M0). Postoperatively, combination chemotherapy with cisplatin (80 mg/m2 i.v. on day 1) and vindesine (3 mg/m2 i.v. on day 1) was begun on September 18, together with thoracic irradiation (2 Gy per day) which commenced on day 3 (Fig 1A) . On day 1 the patient received 3.5 liters of intravenous fluids and diuretics for over 12 hours. On days 2, 3, 4, and 5 he was given 2 liter offluids for 8 hours. Granisetron (3 mg) was also administered intravenously before and after chemotherapy on day 1 , and 4 mg of ondansetron was administered orally everyday between days 2 and 7. However, the patient developed severe emesis on day 3 and had acute-onset syncope with diaphoresis and chest oppressive feeling in the early morning of day 4. The electrocardiogram (ECG) showed ST segment elevation in leads II, III, aVF, V5, and V6 with ventricular arrhythmia ( Fig. 2A) , which had not been observed in the prechemotherapy ECGs. Cardiac enzymes were all within normal limits, and systolic arterial blood pressure had fallen to 76 mmHg. However, the symptoms and ECGfindings gradually resolved within 48 hours following the administration of a calcium antagonist, nitroglycerin tape and lidocaine ( Fig. 2B) . At that time, angina pectoris of variant form was diagnosed. Chemotherapy and irradiation were discontinued, though he had no further anginal episodes.
Vasospastic Angina Related to Chemoirradiation Patient 2 A 61-year-old male smoker (25 cigarettes/day for 35 years) was admitted to our hospital in October 1995 with arm and facial swelling, dyspnea and hoarseness. During the clinical examination at a local hospital, a large massshadowwas detected on a chest radiograph. Physical examination on admission showed edema of the face and neck, engorged veins in the neck and chest, and diminished respiratory sounds in the right lung field. A chest radiograph showed a large mass in the right hilum associated with elevation of the ipsilateral diaphragm. The tumor was histologically diagnosed as small-cell carcinoma by transbronchial biopsy, and the clinical stage was evaluated as a limited disease (T4N3M0). Combination chemotherapy with cisplatin (80 mg/m2 i.v. on day 1) and etoposide (100 mg/m2 i.v. on day 1-3) together with radiotherapy of the chest commenced on October 23, 1995 (Fig. IB) . Hydration was also given as in Patient 1. Granisetron and ondansetron were administered in a manner similar to the schedule used in Patient 1 above. Radiotherapy (42 Gy in 21 daily fractions, 5 fractions per week) was administered to the tumor-bearing area including the mediastinum, and the tumor markedly regressed following two courses of chemotherapy. On day 7 of the third course the patient developed syncopal attack, diaphoresis and severe chest oppressive feeling. The pulse rate decreased to 48 beats/min, and the systolic blood pressure fell to 56 mmHg. ECGtaken immediately after the chest oppressive feeling showed ST segment elevation in leads II, III, aVF, and V,^, and ST depression in leads I and aVL, and complete AVblock (Fig.  3A) . Serial creatine phosphokinase (CPK) and lactate dehydrogenase (LDH) levels were within normal limits. The patient was treated with nitroglycerine sublingually which produced an immediate resolution of symptoms. ECGtaken five hours later showed normal findings (Fig. 3B) . Oral diltiazem and isosorbide dinitrate tape were administered, and three weeks later, the fourth course of chemotherapy was administered but no ischemic event was noted.
Discussion
In cancer patients, CADis usually due to atherosclerotic changes affecting arterial walls rather than due to non-atherosclerotic mechanisms, since cancer is usually more prevalent in elderly than young patients. Thus, the underlying mechanisms of CADin cancer patients whoare treated with anticancer agents mayinclude [1] coexistent coronary atherosclerosis, [2] coronary compression or embolization by the tumor,
[3] tumor-associated hypercoagulopathy, [4] vasculitis, [5] nonbacterial thrombotic endocarditis, and [6] complications directly related to antineoplastic therapy (4, 5) . In the present two cases, vasospastic angina was probably caused by a pre-existing atherosclerotic CAD,radiation-induced CAD,or a direct effect of cisplatin, etoposide or vindesine on the heart. In addition, the vasospasm may be due to the administration of serotonin-antagonist antiemetics used during managementof these patients such as oral ondansetron or intravenous granisetron as reported previously (6, 7) . However, the vasospastic angina is likely to be caused by cisplatin-containing chemotherapy and/or thoracic irradiation, although the exact mechanismwasnot determined precisely in the present study. In patient 1, as the recovery of symptomsand ECGchanges were delayed, myocardial damageswere also considered. However,the patient was diagnosed with vasospastic angina because of the normal echocardiographic images and normal cardiac enzymesafter the attack. Wespeculated that the delay of recovery was due to the repeated spasms of coronary artery. Drug-related CADhas been reported in patients treated with one or moretypes of antineoplastic agents. In particular, a combination chemotherapy regimen consisting of 5-fluorouracil, vinca alkaloids, bleomycin or cisplatin appears to induce CAD (3, [8] [9] [10] . However, it is not clear whether such vascular events are directly caused by chemotherapy or whether they represent a fortuitous association. Though the exact pathogenesis of cytotoxic drug-induced CADremains undetermined, there are several putative mechanisms. These include endothelial cell damagesecondary to antineoplastic agents and/or one of their metabolites, drug-induced perturbation of the clotting system or platelet activation, hypomagnesemia-induced coronary artery spasm and abnormalities of the autonomic nervous system(3).
The two cases described in this report indicate that clinicians should be aware of the potential, although uncommon, development of CADin cancer patients who are treated with antineoplastic agents. Further documentation of such CAD cases will be necessary to elucidate the mechanismsof this toxicity.
